Terumo (4543) Investor Day 2026 summary

Strategic Growth Initiatives and Market Expansion

• Africa is a key growth engine, leveraging government relationships, localized infrastructure, and training programs to drive patient impact and sustainable value, with BCT revenue in Africa expected to grow at 14% CAGR through FY31.

• Expansion in Africa includes building a regional hub in Kenya, government engagement for healthcare funding, and strategic partnerships to scale impact and address unmet needs in transfusion and sickle cell disease.

• China is identified as a key growth market for imaging equipment, with plans to optimize product lineup and consider local partnerships.

• CDMO business in Germany targets both large and small projects, with flexibility in production lines and a strategy favoring larger-scale projects, aiming for 100 billion yen in revenue.

• Two M&As executed in FY25 accelerated business expansion and growth.

Financial Performance and Guidance

• Achieved record-high revenue and profit in FY25, with a 5-year company-wide revenue CAGR of 12%.

• FY26 guidance targets 9% YoY revenue growth (8% excluding FX) and 20% operating profit margin, excluding new M&A.

• All GS26 financial targets are expected to be achieved, with steady operational improvements enhancing profitability.

• Revus identified as the top revenue contributor among growth businesses, with all four highlighted businesses expected to drive growth during the GS31 period.

• Next midterm management plan (GS31) to be announced in December, focusing on both organic and non-organic growth opportunities.

Innovation, Technology, and Product Pipeline

• Emphasis on automation, cloud connectivity, and compact design in next-generation organ perfusion devices, with new products targeting liver and kidney transplantation and future exploration of cardiac applications.

• Integration of Terumo CDI blood gas analyzer enables unique automation and user empowerment, reducing training time and enhancing clinical outcomes.

• AI-powered imaging and treatment support systems are under development to optimize stent placement and plaque assessment.

• Cross-functional innovation teams and streamlined decision-making processes established to accelerate development and leverage core technologies, including coating technology and R&D hubs in Southern California.

• Ongoing studies in organ defatting and reconditioning, with results expected within a couple of years.